CINXE.COM

<!DOCTYPE html> <html class="no-js" lang="en" prefix="og: https://ogp.me/ns#"> <head> <script src="https://sp-library.prod.sp.aws.clarivate.net/oti/latest/index.umd.js"></script> <link href="https://www.bioworld.com/topics/84-bioworld" rel="canonical"> <meta charset="utf-8"> <meta name="csrf-param" content="authenticity_token" /> <meta name="csrf-token" content="7MSkqr45GbS5rwQ7MyhjAMu5suf6FovOcZmYpa4nEUgT2Dnpghc/RaInHkxCUBLWCktZuP8fT7gbp6IbBp4Dwg==" /> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <meta name="timestamp" value="2025-02-21 10:08:13 -0500"> <meta name="description" content="Daily news and analysis of the global biotechnology and pharmaceutical industries. In-depth coverage of business, financing, regulation, science, innovation, drug approvals, clinical trials and more." /> <meta name="keywords" content="news, analysis, biotech, biotechnology, pharma, pharmaceutical, health, business, financing, regulation, science, innovation, drug approvals, FDA, EMA, clinical trials, partnerships, collaborations" /> <link rel="alternate" type="application/xml" title="BioWorld RSS Feed" href="https://www.bioworld.com/rss/articles" /> <meta property="og:title" /> <meta property="og:description" /> <meta property="og:url" /> <meta property="og:type" content="Website" /> <meta content="false" name="has-log-view" /> <title>BioWorld: The Daily Biopharmaceutical News Source</title> <link rel="stylesheet" media="screen" href="/stylesheets/application.css?v=1740150493" /> <script src="/javascripts/jade.default.min.js?v=1740150493"></script> <script src="/javascripts/application.js?v=1740150493"></script>  <script>var dataLayer = window.dataLayer || [];</script> <script>let snowplowData = {"event":"SnowplowStructuredEvent","product":"BIOWORLD"}; fetch('/user/snowplow', { method: 'GET', headers: { 'Content-Type': 'application/json' } }) .then(response => { if (!response.ok) { throw new Error(`HTTP error! status: ${response.status}`); } return response.json(); }) .then(data => { const evt = Object.assign({}, snowplowData, data); console.info('Snowplow Data:', evt); // Handle the fetched data dataLayer.push(evt); }) .catch(error => { console.error('Error fetching snowplow data:', error); // Handle any errors });</script><script>dataLayer.push({"id":84,"topics":["BioWorld"],"title":"BioWorld","page_type":["topics"],"date_posted":"07/19/2019","gated":false,"registered":false});</script> <script>typeof window.dataLayer[0] === 'object' && !('page_type' in window.dataLayer[0]) && window.dataLayer.push({"id":84,"topics":["BioWorld"],"title":"BioWorld","page_type":["topics"],"date_posted":"07/19/2019","gated":false,"registered":false});</script>   <script> //<![CDATA[ (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= '//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-5ZV86V9'); //]]> </script>  <script> window.epub = window.epub || {}; window.epub['AD_HISTORY_ENABLED'] = false; </script> <link rel="apple-touch-icon" sizes="180x180" href="/icons/apple-touch-icon.png"> <link rel="icon" type="image/png" sizes="32x32" href="/icons/favicon-32x32.png"> <link rel="icon" type="image/png" sizes="16x16" href="/icons/favicon-16x16.png"> <link rel="manifest" href="/icons/site.webmanifest"> <link rel="mask-icon" href="/icons/safari-pinned-tab.svg" color="#5bbad5"> <link rel="shortcut icon" href="/icons/favicon.ico"> <meta name="msapplication-TileColor" content="#00aba9"> <meta name="msapplication-config" content="/icons/browserconfig.xml"> <meta name="theme-color" content="#ffffff"><script> var googletag = { cmd: [] }; var targeting = window.targeting = {"id":"84","tags":["BioWorld"],"taxonomy":["BioWorld"],"taxonomy_id":[84],"sponsored":"false","page_type":["topics"],"keyword":[],"reg_user":"false","page_name":"84-bioworld","search_terms":"","url":"/topics/84-bioworld","site_env":"production"}; </script> <script> (function(ac) { var d = document, s = 'script', id = 'adplugg-adjs'; var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) return; js = d.createElement(s); js.id = id; js.async = 1; js.src = '//www.adplugg.com/serve/' + ac + '/js/1.1/ad.js'; fjs.parentNode.insertBefore(js, fjs); }('A48225833')); </script><script>if (typeof Oti !== "undefined" && typeof Oti.OtiService !== "undefined") { $.post('/user/pendo', function(data) { const pendoVisitor = data.visitor const pendoAccount = Object.keys(pendoVisitor).length > 0 ? data.account : '' const anomID = localStorage.getItem('anomID') || (localStorage.setItem('anomID', `${navigator.userAgent}-${screen.width}x${screen.height}-${navigator.language}`.split('').reduce((hash, char) => ((hash << 5) - hash) + char.charCodeAt(0), 0).toString(36)) || localStorage.getItem('anomID')) const pendovistorID = (pendoVisitor && Object.keys(pendoVisitor).length > 0 && pendoVisitor.id) ? `${pendoVisitor.id}` : anomID; const otiService = new Oti.OtiService({ ot_key: "603e2c5b-3a1d-4eac-a9c9-fb20c3b528f2", prod_domain: "www.bioworld.com", pendo_key: "34b78be2-b210-4df9-7f2b-7552afe5341c", pendo_details: { visitor: { id: pendovistorID, firstName: pendoVisitor.first_name, lastName: pendoVisitor.last_name, email: pendoVisitor.email, country: pendoVisitor.country, company: pendoVisitor.company, last_login: pendoVisitor.last_login, opted_out_at: pendoVisitor.opted_out_at, }, account: { id: pendoAccount } }, pendo_visitor_payload: [{ visitorId: pendovistorID, values: { firstName: pendoVisitor.first_name, lastName: pendoVisitor.last_name, email: pendoVisitor.email, country: pendoVisitor.country, company: pendoVisitor.company, last_login: pendoVisitor.last_login, opted_out_at: pendoVisitor.opted_out_at, } }], pendo_visitor_url: '/ui/pendoapi/agent/value?create=true', pendo_dnp_url: `/ui/pendoapi/pendo/value/${pendovistorID}/donotprocess`, pendo_metadata_url: `/ui/pendoapi/custom/value/${pendovistorID}/bioworld_targetingcookies`, }); otiService.initialize(); }); }</script> <link rel="preload" as="script" href="https://cdn.ampproject.org/v0.js"> <script async src="https://cdn.ampproject.org/v0.js"></script>  <style amp-custom>/* Add your styles here */</style> <style amp-boilerplate>body{-webkit-animation:-amp-start 8s steps(1,end) 0s 1 normal both;-moz-animation:-amp-start 8s steps(1,end) 0s 1 normal both;-ms-animation:-amp-start 8s steps(1,end) 0s 1 normal both;animation:-amp-start 8s steps(1,end) 0s 1 normal both}@-webkit-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@-moz-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@-ms-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@-o-keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}@keyframes -amp-start{from{visibility:hidden}to{visibility:visible}}</style><noscript><style amp-boilerplate>body{-webkit-animation:none;-moz-animation:none;-ms-animation:none;animation:none}</style></noscript> <link rel="canonical" href="."> <script async custom-element="amp-iframe" src="https://cdn.ampproject.org/v0/amp-iframe-0.1.js"></script> <script>var _document$querySelect, _document$querySelect2; var $hasLogViewMeta = (_document$querySelect = document.querySelector('meta[name=has-log-view]')) === null || _document$querySelect === void 0 ? void 0 : _document$querySelect.getAttribute('content'); var $logViewUrlMeta = (_document$querySelect2 = document.querySelector('meta[name=log-view-url]')) === null || _document$querySelect2 === void 0 ? void 0 : _document$querySelect2.getAttribute('content'); if ($hasLogViewMeta === 'true') { var baseLogUrl = (typeof $logViewUrlMeta === "undefined" ? window.location.pathname : $logViewUrlMeta).replace(/(\d+)-.*$/, '$1'); var logUrl = baseLogUrl + '/log_view' + window.location.search; if (typeof navigator.sendBeacon === 'function') { navigator.sendBeacon(logUrl); } else { // Gotta love IE var request = new XMLHttpRequest(); request.open('POST', logUrl, true); request.setRequestHeader('Content-Type', 'application/x-www-form-urlencoded; charset=UTF-8'); request.send(); } }</script> </head> <body data-controller="taxonomies" data-action="show" data-prestitial-ad="false" data-poststitial-ad="false" data-news-services="BIOWORLD">  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5ZV86V9" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  <div class="document mmenu-placeholder"><header class="main-header"><div class="main-header__top"><h1> <a href="/" class="main-header__logo" data-eventaction="logo-link" data-eventcategory="click" data-eventlabel="link to homepage" data-eventname="logo-link"> <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 201 36" height="36" fill="none" preservAspectRatio="xMidYMid meet"> <title>BioWorld. Link to homepage.</title> <path fill="#000" d="M17.7999 16.5745v.1066c3.8891 1.5805 6.2511 4.4219 6.2511 8.3111 0 5.3809-3.9958 9.6608-11.0993 9.6608H1V1.01776h10.8506c6.9082 0 10.3712 4.27988 10.3712 8.59527 0 2.93017-1.4385 5.57627-4.4219 6.96147zM7.67732 6.68283v7.49427H11.087c2.3975 0 4.3687-1.2076 4.3687-3.8004 0-2.59283-2.06-3.69387-4.3687-3.69387H7.67732zm0 22.34057h3.46298c4.0313 0 5.9492-1.8646 5.9492-4.6173 0-2.8414-2.3619-4.2798-5.6118-4.2798H7.67732v8.8971zM35.239 34.6352h-6.2333v-16.711h-3.0723V12.632h9.3056v22.0032zM31.8293 1.01776c2.2554 0 4.0313 1.82916 4.0313 4.03125 0 2.25538-1.7759 3.97798-4.0313 3.97798-2.2021 0-3.9957-1.7226-3.9957-3.97798.0178-2.20209 1.7936-4.03125 3.9957-4.03125zM39.217 23.6425c0-6.7128 5.2389-11.5787 11.7564-11.5787 6.5175 0 11.7563 4.8481 11.7563 11.5787s-5.2388 11.5788-11.7563 11.5788c-6.5175 0-11.7564-4.8659-11.7564-11.5788zm6.2511 0c0 3.4097 2.2554 6.0025 5.523 6.0025 3.2144 0 5.4697-2.5928 5.4697-6.0025 0-3.463-2.2553-6.0025-5.4697-6.0025-3.2676 0-5.523 2.5395-5.523 6.0025zM88.7286 1.01776L95.1573 25.081h.0533l5.3814-24.06324h6.819L99.2064 34.6352h-7.7251l-6.3399-24.152-6.1979 24.152h-7.7251L62.9073 1.01776h7.2101L75.303 25.081h.0532l6.4287-24.06324h6.9437zM106.701 23.6425c0-6.7128 5.238-11.5787 11.756-11.5787 6.535 0 11.756 4.8481 11.756 11.5787s-5.239 11.5788-11.756 11.5788c-6.535-.0178-11.756-4.8659-11.756-11.5788zm6.233 0c0 3.4097 2.255 6.0025 5.523 6.0025 3.214 0 5.47-2.5928 5.47-6.0025 0-3.463-2.256-6.0025-5.47-6.0025-3.268 0-5.523 2.5395-5.523 6.0025zm34.772-4.8481h-2.646c-3.161 0-4.618 1.4917-4.618 5.3276v10.5132h-6.233V12.632h6.056v3.4985c.87-2.3441 2.983-3.8004 5.718-3.8004.586 0 1.154.0533 1.723.1954v6.2689zm9.696 15.8408h-6.198V1.01776h6.198V34.6352zm21.559-2.7881c-1.101 1.8292-3.694 3.3564-6.872 3.3564-6.056 0-10.656-4.8481-10.656-11.5787s4.564-11.5788 10.62-11.5788c3.357 0 5.914 1.545 7.015 3.4097 0-.7281-.089-2.5395-.089-4.1733V1h6.233v33.6175h-6.233v-2.7704h-.018zm-11.081-8.2046c0 3.3564 2.308 6.0558 5.612 6.0558 3.303 0 5.611-2.6994 5.611-6.0558 0-3.4097-2.308-6.0025-5.611-6.0025-3.304 0-5.612 2.5928-5.612 6.0025zM191.801 2.58054h2.06V1.01776h-5.772v1.56278h2.043V6.8249h1.669V2.58054zM201 6.8249V1.01776h-2.184l-1.119 2.84141-1.101-2.84141h-2.22V6.8249h1.652V3.13106l1.101 2.66382h1.065l1.101-2.68158v3.7116H201z"/> </svg> </a> </h1><a href='https://clarivate.com/cortellis/' target="_blank" class="main-header__logo -clarivate"> <img src="/images/Cortellis_Flagship_Logo.png" alt="Clarivate" title="Powering insights from Cortellis. Link to Cortellis page on Clarivate website."> </a></div><div class="main-nav-container"><div class="main-nav-container__wrapper"><nav id="main-nav" class="main-nav main-nav--horizontal"><div class="navigation"><ul class="main-nav-level1__items"><li class="main-nav-level1__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld|/topics/84-bioworld" href="/topics/84-bioworld">BioWorld</a></li><li class="main-nav-level1__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld MedTech|/topics/85-bioworld-medtech" href="/topics/85-bioworld-medtech">BioWorld MedTech</a></li><li class="main-nav-level1__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld Asia|/topics/86-bioworld-asia" href="/topics/86-bioworld-asia">BioWorld Asia</a></li><li class="main-nav-level1__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld Science|/topics/520-bioworld-science" href="/topics/520-bioworld-science">BioWorld Science</a></li><li class="main-nav-level1__item"><a class="main-nav__link -has-children" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Data Snapshots|/snapshots" href="/snapshots">Data Snapshots</a><ul class="main-nav-level2__items"><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld|/snapshots" href="/snapshots">BioWorld</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld MedTech|/medtech_snapshots" href="/medtech_snapshots">BioWorld MedTech</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Infographics: Dynamic digital data analysis|/infographics-index" href="/infographics-index">Infographics: Dynamic digital data analysis</a></li></ul></li><li class="main-nav-level1__item"><a class="main-nav__link -has-children" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Special reports|/special_reports" href="/special_reports">Special reports</a><ul class="main-nav-level2__items"><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Infographics: Dynamic digital data analysis|/infographics-index" href="/infographics-index">Infographics: Dynamic digital data analysis</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Trump administration impacts|/Trump_administration_impacts" href="/Trump_administration_impacts">Trump administration impacts</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Biopharma M&A scorecard|/biopharma_MandA_scorecard" href="/biopharma_MandA_scorecard">Biopharma M&A scorecard</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld 2024 review|/BioWorld_2024_review" href="/BioWorld_2024_review">BioWorld 2024 review</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld MedTech 2024 review|https://www.bioworld.com/medtech_trends_2024" href="https://www.bioworld.com/medtech_trends_2024">BioWorld MedTech 2024 review</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="BioWorld Science 2024 review|/BioWorld_Science_2024_review" href="/BioWorld_Science_2024_review">BioWorld Science 2024 review</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Women's health|/womens_health" href="/womens_health">Women's health</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="China's GLP-1 landscape|/China_GLP-1" href="/China_GLP-1">China's GLP-1 landscape</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="PFA re-energizes afib market|https://www.bioworld.com/articles/711618-pulsed-field-ablation-re-energizes-the-atrial-fibrillation-market" href="https://www.bioworld.com/articles/711618-pulsed-field-ablation-re-energizes-the-atrial-fibrillation-market">PFA re-energizes afib market</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="China CAR T|/China_CAR_T" href="/China_CAR_T">China CAR T</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Alzheimer's disease|/Alzheimers" href="/Alzheimers">Alzheimer's disease</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Israel|/israel" href="/israel">Israel</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Rise of obesity|/rise_of_obesity" href="/rise_of_obesity">Rise of obesity</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Radiopharmaceuticals|/radiopharmaceuticals" href="/radiopharmaceuticals">Radiopharmaceuticals</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Biosimilars|/biosimilars" href="/biosimilars">Biosimilars</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Aging|/aging" href="/aging">Aging</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="IVDs on the rise|/IVDs-2021" href="/IVDs-2021">IVDs on the rise</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Coronavirus|/articles/topic/517" href="/articles/topic/517">Coronavirus</a></li><li class="main-nav-level2__item"><a class="main-nav__link" data-eventname="main-nav" data-eventcategory="click" data-eventaction="main-nav-link" data-eventlabel="Artificial intelligence|/AI_series" href="/AI_series">Artificial intelligence</a></li></ul></li></ul></div></nav><div class="main-nav-container__mobile-nav"><a class="hamburger-nav-link" href="#" id="hamburger-nav-link"></a><h1> <a href="/" class="main-header__logo" data-eventaction="logo-link" data-eventcategory="click" data-eventlabel="link to homepage" data-eventname="logo-link"> <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 201 36" height="36" fill="none" preservAspectRatio="xMidYMid meet"> <title>BioWorld. Link to homepage.</title> <path fill="#000" d="M17.7999 16.5745v.1066c3.8891 1.5805 6.2511 4.4219 6.2511 8.3111 0 5.3809-3.9958 9.6608-11.0993 9.6608H1V1.01776h10.8506c6.9082 0 10.3712 4.27988 10.3712 8.59527 0 2.93017-1.4385 5.57627-4.4219 6.96147zM7.67732 6.68283v7.49427H11.087c2.3975 0 4.3687-1.2076 4.3687-3.8004 0-2.59283-2.06-3.69387-4.3687-3.69387H7.67732zm0 22.34057h3.46298c4.0313 0 5.9492-1.8646 5.9492-4.6173 0-2.8414-2.3619-4.2798-5.6118-4.2798H7.67732v8.8971zM35.239 34.6352h-6.2333v-16.711h-3.0723V12.632h9.3056v22.0032zM31.8293 1.01776c2.2554 0 4.0313 1.82916 4.0313 4.03125 0 2.25538-1.7759 3.97798-4.0313 3.97798-2.2021 0-3.9957-1.7226-3.9957-3.97798.0178-2.20209 1.7936-4.03125 3.9957-4.03125zM39.217 23.6425c0-6.7128 5.2389-11.5787 11.7564-11.5787 6.5175 0 11.7563 4.8481 11.7563 11.5787s-5.2388 11.5788-11.7563 11.5788c-6.5175 0-11.7564-4.8659-11.7564-11.5788zm6.2511 0c0 3.4097 2.2554 6.0025 5.523 6.0025 3.2144 0 5.4697-2.5928 5.4697-6.0025 0-3.463-2.2553-6.0025-5.4697-6.0025-3.2676 0-5.523 2.5395-5.523 6.0025zM88.7286 1.01776L95.1573 25.081h.0533l5.3814-24.06324h6.819L99.2064 34.6352h-7.7251l-6.3399-24.152-6.1979 24.152h-7.7251L62.9073 1.01776h7.2101L75.303 25.081h.0532l6.4287-24.06324h6.9437zM106.701 23.6425c0-6.7128 5.238-11.5787 11.756-11.5787 6.535 0 11.756 4.8481 11.756 11.5787s-5.239 11.5788-11.756 11.5788c-6.535-.0178-11.756-4.8659-11.756-11.5788zm6.233 0c0 3.4097 2.255 6.0025 5.523 6.0025 3.214 0 5.47-2.5928 5.47-6.0025 0-3.463-2.256-6.0025-5.47-6.0025-3.268 0-5.523 2.5395-5.523 6.0025zm34.772-4.8481h-2.646c-3.161 0-4.618 1.4917-4.618 5.3276v10.5132h-6.233V12.632h6.056v3.4985c.87-2.3441 2.983-3.8004 5.718-3.8004.586 0 1.154.0533 1.723.1954v6.2689zm9.696 15.8408h-6.198V1.01776h6.198V34.6352zm21.559-2.7881c-1.101 1.8292-3.694 3.3564-6.872 3.3564-6.056 0-10.656-4.8481-10.656-11.5787s4.564-11.5788 10.62-11.5788c3.357 0 5.914 1.545 7.015 3.4097 0-.7281-.089-2.5395-.089-4.1733V1h6.233v33.6175h-6.233v-2.7704h-.018zm-11.081-8.2046c0 3.3564 2.308 6.0558 5.612 6.0558 3.303 0 5.611-2.6994 5.611-6.0558 0-3.4097-2.308-6.0025-5.611-6.0025-3.304 0-5.612 2.5928-5.612 6.0025zM191.801 2.58054h2.06V1.01776h-5.772v1.56278h2.043V6.8249h1.669V2.58054zM201 6.8249V1.01776h-2.184l-1.119 2.84141-1.101-2.84141h-2.22V6.8249h1.652V3.13106l1.101 2.66382h1.065l1.101-2.68158v3.7116H201z"/> </svg> </a> </h1><a class="search-nav-link" href="#" id="search-nav-link"></a><form action="/search" class="mobile-search" id="mobile-search" method="get"><input class="mobile-search__field" name="q" placeholder="What are you looking for?" type="text" /><button class="mobile-search__icon" type="submit"></button></form></div><div class="main-nav-container__nav2"><nav class="user-actions" id="user-actions"> <ul class="user-actions__list"> <li class="user-actions__signin"> <a class="user-actions__signin-link" href="/user/login">Sign In</a> </li> <li class="user-actions__signout"> <a class="user-actions__signout-link" href="/user/logout">Sign Out</a> </li> <li class="user-actions__account"> <a class="user-actions__account-link" href="/user/profile">My Account</a> </li> </ul> </nav> <a class="main-nav-container__subscribe-link" href="/subscriptions">Subscribe</a><div class="quick-search" id="quick-search"><form action="/search" id="quick-search-form" method="GET" name="quick-search" target="_top"><div class="quick-search__wrapper" role="presentation"><input class="quick-search__search-field" id="q" name="q" placeholder="Search" type="text" /><button class="quick-search__button" title="Search" type="submit"></button></div></form></div></div></div></div></header><div class="container container-full"><section class="site-banner" id="site-banner"><div class="site-banner__date">BioWorld - Friday, February 21, 2025</div><a class="site-banner__breaking-news" id="BREAKING_BIOWORLD" href="/articles/716554-bioworld-by-clarivate-releases-comprehensive-2024-year-in-review">Breaking News: BioWorld by Clarivate releases comprehensive 2024 year in review</a><a class="site-banner__breaking-news" id="BREAKING_BIOWORLD_MEDTECH" href="/articles/717493-five-med-tech-trends-to-watch-in-2025">Breaking News: Five med-tech trends to watch in 2025</a><a class="site-banner__breaking-news" id="BREAKING_BIOWORLD_ASIA" href="/articles/716554-bioworld-by-clarivate-releases-comprehensive-2024-year-in-review">Breaking News: BioWorld by Clarivate releases comprehensive 2024 year in review</a></section><section class="featured-stories__wrapper -primary-3 --secondary-3"><div class="featured-stories__primary "><section class="featured-stories "> <div class="featured-stories__items-wrapper"><ul class="featured-stories__items featured-stories__items-1"> <li class="featured-stories__item"> <article class="featured-stories__article -has-image featured-stories--article"><figure class="featured-stories__image"><a class="featured-stories__thumbnail-link" data-eventname="featured-stories" data-eventcategory="click" data-eventaction="featured-stories-image" data-eventlabel="https://www.bioworld.com/articles/717647-radiance-wins-ror1-adc-rights-from-cspc-in-potential-1b-deal" href="https://www.bioworld.com/articles/717647-radiance-wins-ror1-adc-rights-from-cspc-in-potential-1b-deal"><img class="featured-stories__image-thumb" alt="3D illustration demonstrating antibody-drug conjugate." title="3D illustration demonstrating antibody-drug conjugate." width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/BWS/BWS-library/Antibody-Drug-Conjugate-Molecules-ADC.png?height=355&t=1671207526&width=640" /></a></figure><div class="featured-stories__details featured-stories__details-1"><h1 class="featured-stories__headline"><a class="featured-stories__article-title-link" href="https://www.bioworld.com/articles/717647-radiance-wins-ror1-adc-rights-from-cspc-in-potential-1b-deal">Radiance wins ROR1 ADC rights from CSPC in potential $1B+ deal</a></h1><div class="featured-stories__teaser">Radiance Biopharma Inc. bought its way into the ROR1 antibody-drug conjugate (ADC) space through a potential $1 billion-plus licensing deal, including a $15 million up-front payment, with CSPC Megalith Biopharmaceutical Co. Ltd. for rights to RB-164 (SYS-6005) in the U.S. and select countries.</div></div></article> </li> </ul><ul class="featured-stories__items featured-stories__items-2"> <li class="featured-stories__item"> <article class="featured-stories__article -has-image featured-stories--article"><h1 class="featured-stories__headline"><a class="featured-stories__article-title-link" href="https://www.bioworld.com/articles/717644-incyte-joins-the-group-getting-guidance-from-ais-genesis">Incyte joins the group getting guidance from AI’s Genesis</a></h1></article> </li> <li class="featured-stories__item"> <article class="featured-stories__article featured-stories--article"><h1 class="featured-stories__headline"><a class="featured-stories__article-title-link" href="https://www.bioworld.com/articles/432891-todays-news-in-brief">Today's news in brief</a></h1></article> </li> </ul></div> </section></div><div class="featured-stories__secondary"><section class="featured-stories "> <ul class="featured-stories__items"> <li class="featured-stories__item"> <article class="featured-stories__article -has-image featured-stories--article"><h1 class="featured-stories__headline"><a class="featured-stories__article-title-link" href="https://www.bioworld.com/articles/717647-radiance-wins-ror1-adc-rights-from-cspc-in-potential-1b-deal">Radiance wins ROR1 ADC rights from CSPC in potential $1B+ deal</a></h1><div class="featured-stories__teaser">Radiance Biopharma Inc. bought its way into the ROR1 antibody-drug conjugate (ADC) space through a potential $1 billion-plus licensing deal, including a $15 million up-front payment, with CSPC Megalith Biopharmaceutical Co. Ltd. for rights to RB-164 (SYS-6005) in the U.S. and select countries.</div></article> </li> <li class="featured-stories__item"> <article class="featured-stories__article -has-image featured-stories--article"><h1 class="featured-stories__headline"><a class="featured-stories__article-title-link" href="https://www.bioworld.com/articles/717644-incyte-joins-the-group-getting-guidance-from-ais-genesis">Incyte joins the group getting guidance from AI’s Genesis</a></h1><div class="featured-stories__teaser">Artificial intelligence (AI) technology developer Genesis Therapeutics Inc. has brought in another larger partner to go on a search for the right therapeutic small molecules. The company is getting an up-front $30 million payment from Incyte Corp. and could bring in as much as $295 million per target in development, regulatory and commercial milestones, bringing the deal to about $620 million total.</div></article> </li> <li class="featured-stories__item"> <article class="featured-stories__article featured-stories--article"><h1 class="featured-stories__headline"><a class="featured-stories__article-title-link" href="https://www.bioworld.com/articles/432891-todays-news-in-brief">Today's news in brief</a></h1><div class="featured-stories__teaser"><em>BioWorld</em> briefs for Feb. 20, 2025.</div></article> </li> <li class="featured-stories__item"> <article class="featured-stories__article -has-image featured-stories--article"><h1 class="featured-stories__headline"><a class="featured-stories__article-title-link" href="https://www.bioworld.com/articles/717648-still-waiting-for-the-dust-to-settle-at-us-fda-throughout-hhs">Still waiting for the dust to settle at US FDA, throughout HHS</a></h1><div class="featured-stories__teaser">With massive terminations, data removals, holds on U.S. government funding, cancellation of various programs and meetings, the potential for 25% tariffs on medical products and a multitude of court challenges and appeals, the dust is flying thick at the FDA, NIH and throughout the Department of Health and Human Services (HHS).</div></article> </li> <li class="featured-stories__item"> <article class="featured-stories__article -has-image featured-stories--article"><h1 class="featured-stories__headline"><a class="featured-stories__article-title-link" href="https://www.bioworld.com/articles/717645-eg-427-adds-27m-series-b-for-neurogenic-bladder-program">EG 427 adds €27M series B for neurogenic bladder program </a></h1><div class="featured-stories__teaser">EG 427 SAS has closed a €27 million (US$28.3 million) series B round, which will fund it to completion of the first clinical trial of the lead gene therapy program, opening the way for its herpes simplex viral-vectored products to be developed in a range of chronic neuro-urology disorders.</div></article> </li> <li class="featured-stories__item"> <article class="featured-stories__article -has-image featured-stories--article"><h1 class="featured-stories__headline"><a class="featured-stories__article-title-link" href="https://www.bioworld.com/articles/717646-trial-begins-for-inhaled-gene-therapy-for-cystic-fibrosis">Trial begins for inhaled gene therapy for cystic fibrosis</a></h1><div class="featured-stories__teaser">The longstanding ambition of developing an inhaled gene therapy for cystic fibrosis has taken a step forward, with the start of a phase I/II trial of a product using a novel pseudotyped viral vector that it is hoped will circumvent problems encountered in previous studies with other vectors.</div></article> </li> </ul> </section></div><div class="news-service"><div class="news-service__infogram"><script id="infogram_0_e8cdbb9c-eb05-4408-92a9-279df0bf8849" title="BW deals W" src="https://e.infogram.com/js/dist/embed.js?z7d" type="text/javascript"></script></div></div></section><div class="topic-podcast"><div class="adplugg-tag" data-adplugg-zone="bioworld_banner"></div><section class="bioworld-podcasts-component"><div class="bioworld-podcasts-component__wrapper"><div class="bioworld-podcasts-component__content"><h3 class="bioworld-podcasts-component__headline"><a class="bioworld-podcasts-component__headline-link" href="https://www.bioworld.com/media/podcasts/532-bioworld-insider-podcast">BioWorld Insider Podcast</a></h3><div class="bioworld-podcasts-component__body"><img src="https://www.bioworld.com/ext/resources/Podcast-files/play-circle-button.png?1718131949" style="display: inline-block; vertical-align: bottom; margin: 5px 0px 5px 5px; text-align: right; float: right; max-width: calc(100% - 5px); width: 95px;" alt="Play button" data-uuid="YTAtMTE1OTM1" align="right">The <em>BioWorld Insider</em> podcast is a monthly dive into the business and science of drug development. Conversations with CEOs and <em>BioWorld</em> analysts in the past 12 months have included a wide range of chats with experts who are shaping the future.</div><a class="bioworld-podcasts-component__link" href="https://www.bioworld.com/media/podcasts/532-bioworld-insider-podcast">Listen now</a><div class="bioworld-podcasts-component__adplugg-ad"><div class="adplugg-tag" data-adplugg-zone="bioworld_podcasts_bioworld"></div></div></div></div></section></div><section class="topics-section__wrapper"><div class="topics-section__primary"><section class="topics-section "> <h1 class="topics-section__title"><a class="topics-section__title-link" data-eventname="topics-section" data-eventcategory="click" data-eventaction="topics-section-title" data-eventlabel="/articles/topic/109-analysis-and-data-insight" href="/articles/topic/109-analysis-and-data-insight">Analysis and data insight</a></h1><ul class="topics-section__items"> <li class="topics-section__item"> <article class="topics-section__article -has-image topics-section--article"><figure class="topics-section__image"><a class="topics-section__thumbnail-link" data-eventname="topics-section" data-eventcategory="click" data-eventaction="topics-section-image" data-eventlabel="https://www.bioworld.com/articles/717425-copper-wired-monopar-to-electrify-wilson-disease" href="https://www.bioworld.com/articles/717425-copper-wired-monopar-to-electrify-wilson-disease"><img class="topics-section__image-thumb" alt="Copper-colored DNA on blue background" title="Copper-colored DNA on blue background" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Copper-colored-DNA-on-blue-background.jpg?height=355&t=1739999659&width=640" /></a></figure><div class="topics-section__details topics-section__details-1"><h1 class="topics-section__headline"><a class="topics-section__article-title-link" href="https://www.bioworld.com/articles/717425-copper-wired-monopar-to-electrify-wilson-disease">Copper wired: Monopar to electrify Wilson disease?</a></h1><div class="topics-section__topics"><a class="topics-section__topic-link" href="/articles/topic/246,84">Endocrine/metabolic</a></div><div class="topics-section__teaser">Research seems to be gaining ground in Wilson disease, a rare inherited condition that causes copper levels to accumulate in the liver, brain and eyes. Most people are diagnosed as children or around middle age, but the age spectrum can be wide. Monopar Therapeutics Inc. has drawn Wall Street’s...</div></div></article> </li> <li class="topics-section__item"> <article class="topics-section__article -has-image topics-section--article"><figure class="topics-section__image"><a class="topics-section__thumbnail-link" data-eventname="topics-section" data-eventcategory="click" data-eventaction="topics-section-image" data-eventlabel="https://www.bioworld.com/articles/717423-drug-developers-struggle-in-2024-fibrogen-acadia-atai-post-gains" href="https://www.bioworld.com/articles/717423-drug-developers-struggle-in-2024-fibrogen-acadia-atai-post-gains"><img class="topics-section__image-thumb" alt="Drug R&D concept image." title="Drug R&D concept image." width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/BWS/BWS-library/Science-research-drug-development.png?height=355&t=1663861988&width=640" /></a></figure><div class="topics-section__details topics-section__details-1"><h1 class="topics-section__headline"><a class="topics-section__article-title-link" href="https://www.bioworld.com/articles/717423-drug-developers-struggle-in-2024-fibrogen-acadia-atai-post-gains">Drug developers struggle in 2024; Fibrogen, Acadia, Atai post gains</a></h1><div class="topics-section__teaser">The BioWorld Drug Developers Index extended its decline through year-end, closing 2024 down 15.25%. After dropping 11.3% by October, the index briefly rebounded, narrowing losses to 5.36% in November, before slipping again.</div></div></article> </li> <li class="topics-section__item"> <article class="topics-section__article -has-image topics-section--article"><figure class="topics-section__image"><a class="topics-section__thumbnail-link" data-eventname="topics-section" data-eventcategory="click" data-eventaction="topics-section-image" data-eventlabel="https://www.bioworld.com/articles/717357-aaas-2025-former-nih-head-bertagnolli-sounds-warning-on-funding-cuts" href="https://www.bioworld.com/articles/717357-aaas-2025-former-nih-head-bertagnolli-sounds-warning-on-funding-cuts"><img class="topics-section__image-thumb" alt="Monica Bertagnolli, former director, U.S. NIH" title="Monica Bertagnolli, former director, U.S. NIH" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/Monica-Bertagnolli-former-director-U.S.-NIH.jpg?height=355&t=1739916924&width=640" /></a></figure><div class="topics-section__details topics-section__details-1"><h1 class="topics-section__headline"><a class="topics-section__article-title-link" href="https://www.bioworld.com/articles/717357-aaas-2025-former-nih-head-bertagnolli-sounds-warning-on-funding-cuts">AAAS 2025: Former NIH head Bertagnolli sounds warning on funding cuts</a></h1><div class="topics-section__topics"><a class="topics-section__topic-link" href="/articles/topic/402,84">Regulatory</a></div><div class="topics-section__teaser">The former head of the U.S. NIH has sounded a warning that the uncertainty caused by the Trump Administration’s funding cuts and layoffs is blocking “critical work” and “paralyzing” biomedical research. “Every time we launch a new program, every time we continue to commit resources to ongoing work,...</div></div></article> </li> <li class="topics-section__item"> <article class="topics-section__article -has-image topics-section--article"><figure class="topics-section__image"><a class="topics-section__thumbnail-link" data-eventname="topics-section" data-eventcategory="click" data-eventaction="topics-section-image" data-eventlabel="https://www.bioworld.com/articles/717342-biopharma-kicks-off-strong-in-2025-with-286b-in-january-deals" href="https://www.bioworld.com/articles/717342-biopharma-kicks-off-strong-in-2025-with-286b-in-january-deals"><img class="topics-section__image-thumb" alt="Handshake" title="Handshake" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-handshake-black-white.png?height=355&t=1588280123&width=640" /></a></figure><div class="topics-section__details topics-section__details-1"><h1 class="topics-section__headline"><a class="topics-section__article-title-link" href="https://www.bioworld.com/articles/717342-biopharma-kicks-off-strong-in-2025-with-286b-in-january-deals">Biopharma kicks off strong in 2025, with $28.6B in January deals </a></h1><div class="topics-section__topics"><a class="topics-section__topic-link" href="/articles/topic/214,84">Deals and M&A</a></div><div class="topics-section__teaser">Biopharma deal activity in the first month of the year saw the largest January raise thus far, with $28.63 billion in collective funds. While down slightly month over month, the value was comparable to December 2024’s $29.02 billion and November 2024’s $29.34 billion.</div></div></article> </li> </ul><a class="topics-section__more-link" data-eventname="topics-section" data-eventcategory="click" data-eventaction="topics-section-more-link" data-eventlabel="/articles/topic/109-analysis-and-data-insight" href="/articles/topic/109-analysis-and-data-insight">More in Analysis and data insight</a> </section></div><div class="topics-section__aside"><section class="news-in-brief "> <h1 class="news-in-brief__title">Today's news in brief</h1><ul class="news-in-brief__items"> <li class="news-in-brief__item"> <article class="news-in-brief__article news-in-brief--article"><h1 class="news-in-brief__headline"><a class="news-in-brief__article-title-link" href="https://www.bioworld.com/articles/717650-appointments-and-advancements-for-feb-20-2025">Appointments and advancements for Feb. 20, 2025</a></h1></article> </li> <li class="news-in-brief__item"> <article class="news-in-brief__article news-in-brief--article"><h1 class="news-in-brief__headline"><a class="news-in-brief__article-title-link" href="https://www.bioworld.com/articles/717651-financings-for-feb-20-2025">Financings for Feb. 20, 2025</a></h1></article> </li> <li class="news-in-brief__item"> <article class="news-in-brief__article news-in-brief--article"><h1 class="news-in-brief__headline"><a class="news-in-brief__article-title-link" href="https://www.bioworld.com/articles/717652-in-the-clinic-for-feb-20-2025">In the clinic for Feb. 20, 2025</a></h1></article> </li> <li class="news-in-brief__item"> <article class="news-in-brief__article news-in-brief--article"><h1 class="news-in-brief__headline"><a class="news-in-brief__article-title-link" href="https://www.bioworld.com/articles/717653-other-news-to-note-for-feb-20-2025">Other news to note for Feb. 20, 2025</a></h1></article> </li> <li class="news-in-brief__item"> <article class="news-in-brief__article news-in-brief--article"><h1 class="news-in-brief__headline"><a class="news-in-brief__article-title-link" href="https://www.bioworld.com/articles/717654-regulatory-actions-for-feb-20-2025">Regulatory actions for Feb. 20, 2025</a></h1></article> </li> </ul> </section></div></section><section class="topics-section-2__wrapper"><div class="topics-section-2__aside"><section class="asia-pacific "> <h1 class="asia-pacific__title"><a class="asia-pacific__title-link" data-eventname="asia-pacific" data-eventcategory="click" data-eventaction="asia-pacific-title" data-eventlabel="/articles/topic/214-deals-and-m-a" href="/articles/topic/214-deals-and-m-a">Deals and M&A</a></h1><ul class="asia-pacific__items"> <li class="asia-pacific__item"> <article class="asia-pacific__article -has-image asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717260-ligachem-gets-rights-to-daans-antibody-for-solid-tumor-adcs">Ligachem gets rights to Daan’s antibody for solid tumor ADCs</a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article -has-image asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717211-apac-deals-abound-lilly-taps-advancell-olix-genome-draws-ellipses">APAC deals abound: Lilly taps Advancell, Olix; Genome draws Ellipses</a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717208-abbvie-engaged-again-vows-21b-pus-in-xilio-t-cell-pact">Abbvie engaged again, vows $2.1B-plus in Xilio T cell pact</a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article -has-image asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717104-novartis-paying-up-to-31b-for-cardio-specialist-anthos">Novartis paying up to $3.1B for cardio specialist Anthos</a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article -has-image asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717092-olix-wins-630m-deal-from-eli-lilly-for-phase-i-mash-asset">Olix wins $630M deal from Eli Lilly for phase I MASH asset</a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article -has-image asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717075-tyk2s-to-tango-ted-dead-alumis-acelyrin-merger-a-capital-idea">TYK2s to tango, TED dead? Alumis/Acelyrin merger a capital idea</a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article -has-image asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717000-low-sales-safety-concerns-doom-biopharmas-roi-for-mega-m-and-as">Low sales, safety concerns doom biopharma’s ROI for mega-M&As</a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article -has-image asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/716978-chinese-biotechs-aim-to-clear-high-hurdles-with-overseas-spinouts">Chinese biotechs aim to clear high hurdles with overseas spinouts</a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article -has-image asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/716977-few-biopharma-mega-mergers-hit-the-jackpot">Few biopharma mega-mergers hit the jackpot</a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article -has-image asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/716959-a-biopharma-m-and-a-scorecard-some-wins-lots-of-losses">A biopharma M&A scorecard: Some wins, lots of losses</a></h1></article> </li> </ul> </section></div><div class="topics-section-2__row"><div class="topics-section-2__col -one"><section class="bioworld-biome "> <h1 class="bioworld-biome__title"><a class="bioworld-biome__title-link" data-eventname="bioworld-biome" data-eventcategory="click" data-eventaction="bioworld-biome-title" data-eventlabel="/articles/topic/292-financings" href="/articles/topic/292-financings">Financings</a></h1><div class="bioworld-biome__items-wrapper"><ul class="bioworld-biome__items bioworld-biome__items-1"> <li class="bioworld-biome__item"> <article class="bioworld-biome__article bioworld-biome--article"><div class="bioworld-biome__details bioworld-biome__details-1"><h1 class="bioworld-biome__headline"><a class="bioworld-biome__article-title-link" href="https://www.bioworld.com/articles/717656-arcus-prices-150m-stock-offering-to-drive-its-cancer-therapy">Arcus prices $150M stock offering to drive its cancer therapy</a></h1><div class="bioworld-biome__topics"><a class="bioworld-biome__topic-link" href="/articles/topic/239,84">Cancer</a></div><div class="bioworld-biome__teaser">With Gilead Sciences Inc. stepping away from its exclusive option rights to casdatifan in treating cancer, Arcus Biosciences Inc. has decided to move on by pricing a $150 million common stock offering. Arcus said Gilead’s rights to the HIF-2a inhibitor, which just produced positive early phase...</div></div></article> </li> </ul><ul class="bioworld-biome__items bioworld-biome__items-2"> <li class="bioworld-biome__item"> <article class="bioworld-biome__article -has-image bioworld-biome--article"><h1 class="bioworld-biome__headline"><a class="bioworld-biome__article-title-link" href="https://www.bioworld.com/articles/717340-dac-specialist-orum-raises-35m-with-kosdaq-ipo">DAC specialist Orum raises $35M with Kosdaq IPO</a></h1><div class="bioworld-biome__topics"><a class="bioworld-biome__topic-link" href="/articles/topic/239,84">Cancer</a></div></article> </li> <li class="bioworld-biome__item"> <article class="bioworld-biome__article bioworld-biome--article"><h1 class="bioworld-biome__headline"><a class="bioworld-biome__article-title-link" href="https://www.bioworld.com/articles/717259-aardvark-stock-sinks-first-day-ipo-to-fund-obesity-drugs">Aardvark stock sinks first day; IPO to fund obesity drugs</a></h1><div class="bioworld-biome__topics"><a class="bioworld-biome__topic-link" href="/articles/topic/246,84">Endocrine/metabolic</a></div></article> </li> <li class="bioworld-biome__item"> <article class="bioworld-biome__article bioworld-biome--article"><h1 class="bioworld-biome__headline"><a class="bioworld-biome__article-title-link" href="https://www.bioworld.com/articles/717091-bio-ceo-2025-a-nice-upswing-in-vc-rounds-but-uncertainty-looms">BIO CEO 2025: A ‘nice upswing’ in VC rounds, but uncertainty looms</a></h1><div class="bioworld-biome__topics"><a class="bioworld-biome__topic-link" href="/articles/topic/154,84">Conferences</a></div></article> </li> <li class="bioworld-biome__item"> <article class="bioworld-biome__article bioworld-biome--article"><h1 class="bioworld-biome__headline"><a class="bioworld-biome__article-title-link" href="https://www.bioworld.com/articles/717203-my-sionna-ipo-upsized-to-pretty-one-at-191m">My, Sionna: IPO upsized to pretty one at $191M</a></h1><div class="bioworld-biome__topics"><a class="bioworld-biome__topic-link" href="/articles/topic/263,84">Respiratory</a></div></article> </li> </ul></div><a class="bioworld-biome__more-link" data-eventname="bioworld-biome" data-eventcategory="click" data-eventaction="bioworld-biome-more-link" data-eventlabel="/articles/topic/292-financings" href="/articles/topic/292-financings">More in Financings</a> </section></div><div class="adplugg-tag" data-adplugg-zone="bioworld_promo_1"></div></div><div class="topics-section-2__row"><div class="topics-section-2__col -three"><section class="clinical "> <h1 class="clinical__title"><a class="clinical__title-link" data-eventname="clinical" data-eventcategory="click" data-eventaction="clinical-title" data-eventlabel="/articles/topic/110-science" href="/articles/topic/110-science">Science</a></h1><div class="clinical__items-wrapper"><ul class="clinical__items clinical__items-1"> <li class="clinical__item"> <article class="clinical__article -has-image clinical--article"><figure class="clinical__image"><a class="clinical__thumbnail-link" data-eventname="clinical" data-eventcategory="click" data-eventaction="clinical-image" data-eventlabel="https://www.bioworld.com/articles/717368-guk1-is-metabolic-gate-in-alk-driven-lung-cancer" href="https://www.bioworld.com/articles/717368-guk1-is-metabolic-gate-in-alk-driven-lung-cancer"><img class="clinical__image-thumb" alt="Lung cancer illustration" title="Lung cancer illustration" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/lung-cancer.png?height=355&t=1588884954&width=640" /></a></figure><div class="clinical__details clinical__details-1"><h1 class="clinical__headline"><a class="clinical__article-title-link" href="https://www.bioworld.com/articles/717368-guk1-is-metabolic-gate-in-alk-driven-lung-cancer">GUK1 is metabolic gate in ALK-driven lung cancer</a></h1><div class="clinical__topics"><a class="clinical__topic-link" href="/articles/topic/239,84">Cancer</a></div><div class="clinical__teaser">Using ALK+ lung cancer patient-derived cell lines, researchers have performed phosphoproteomic screening and identified guanylate kinase 1 (GUK1) as a TKI sensitive metabolic molecule in ALK-driven lung cancer. They reported their results online in <em>Cell</em> on Feb. 6, 2025.</div></div></article> </li> </ul><ul class="clinical__items clinical__items-2"> <li class="clinical__item"> <article class="clinical__article -has-image clinical--article"><h1 class="clinical__headline"><a class="clinical__article-title-link" href="https://www.bioworld.com/articles/717338-trump-administration-an-existential-threat-to-science-warns-aaas-chief">Trump administration an existential threat to science, warns AAAS chief</a></h1><div class="clinical__topics"><a class="clinical__topic-link" href="/articles/topic/401,84">U.S.</a></div><div class="clinical__teaser">The scientific establishment has launched a fight back against the Trump administration and the slew of executive orders that threaten to dismantle research funding, with a warning that the next month could be critical for the future of U.S. science.</div></article> </li> <li class="clinical__item"> <article class="clinical__article -has-image clinical--article"><h1 class="clinical__headline"><a class="clinical__article-title-link" href="https://www.bioworld.com/articles/717284-insights-into-extracellular-matrix-are-metastasis-map">Insights into extracellular matrix are metastasis map</a></h1><div class="clinical__topics"><a class="clinical__topic-link" href="/articles/topic/239,84">Cancer</a></div><div class="clinical__teaser">New research has uncovered a complex interplay between extracellular matrix (ECM) structure and the transcriptional responses of cancer cells, showing how they alter their gene expression to ‘escape’ from ECM. The findings will make it easier to identify tumors that are likely to metastasize at an...</div></article> </li> </ul><ul class="clinical__items clinical__items-3"> <li class="clinical__item"> <article class="clinical__article -has-image clinical--article"><h1 class="clinical__headline"><a class="clinical__article-title-link" href="https://www.bioworld.com/articles/717184-olig2-inhibitor-shows-promise-in-treatment-resistant-brain-tumors-in-preclinical-models">OLIG2 inhibitor shows promise in treatment-resistant brain tumors in preclinical models</a></h1><div class="clinical__topics"><a class="clinical__topic-link" href="/articles/topic/239,84">Cancer</a></div></article> </li> <li class="clinical__item"> <article class="clinical__article -has-image clinical--article"><h1 class="clinical__headline"><a class="clinical__article-title-link" href="https://www.bioworld.com/articles/717074-genomic-study-paves-way-for-multimorbidity-treatments">Genomic study paves way for multimorbidity treatments</a></h1><div class="clinical__topics"><a class="clinical__topic-link" href="/articles/topic/153,84">Clinical</a></div></article> </li> <li class="clinical__item"> <article class="clinical__article -has-image clinical--article"><h1 class="clinical__headline"><a class="clinical__article-title-link" href="https://www.bioworld.com/articles/717051-targeting-translation-could-be-novel-way-to-fight-myc-other-oncogenes">Targeting translation could be novel way to fight Myc, other oncogenes</a></h1><div class="clinical__topics"><a class="clinical__topic-link" href="/articles/topic/239,84">Cancer</a></div></article> </li> <li class="clinical__item"> <article class="clinical__article -has-image clinical--article"><h1 class="clinical__headline"><a class="clinical__article-title-link" href="https://www.bioworld.com/articles/716761-antibody-prevents-severe-bird-flu-in-macaques">Antibody prevents severe bird flu in macaques </a></h1><div class="clinical__topics"><a class="clinical__topic-link" href="/articles/topic/250,84">Immune</a></div></article> </li> </ul></div><a class="clinical__more-link" data-eventname="clinical" data-eventcategory="click" data-eventaction="clinical-more-link" data-eventlabel="/articles/topic/110-science" href="/articles/topic/110-science">More in Science</a> </section></div></div></section><div class="deals-m-a__wrapper"><section class="deals-m-a "> <h1 class="deals-m-a__title"><a class="deals-m-a__title-link" data-eventname="deals-m-a" data-eventcategory="click" data-eventaction="deals-m-a-title" data-eventlabel="/articles/topic/391-newco-news" href="/articles/topic/391-newco-news">Newco news</a></h1><ul class="deals-m-a__items"> <li class="deals-m-a__item"> <article class="deals-m-a__article -has-image deals-m-a--article"><figure class="deals-m-a__image"><a class="deals-m-a__thumbnail-link" data-eventname="deals-m-a" data-eventcategory="click" data-eventaction="deals-m-a-image" data-eventlabel="https://www.bioworld.com/articles/717209-biomissiles-multispecific-antibodies-harness-nk-cell-engagers" href="https://www.bioworld.com/articles/717209-biomissiles-multispecific-antibodies-harness-nk-cell-engagers"><img class="deals-m-a__image-thumb" alt="Chao Tu, co-founder and CEO, Biomissile Pharmaceuticals " title="Chao Tu, co-founder and CEO, Biomissile Pharmaceuticals " width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/BW-source/2025/Chao-Tu-co-founder-and-CEO-Biomissile-Pharmaceuticals-2-12.jpg?height=355&t=1739393041&width=640" /></a></figure><div class="deals-m-a__details deals-m-a__details-1"><h1 class="deals-m-a__headline"><a class="deals-m-a__article-title-link" href="https://www.bioworld.com/articles/717209-biomissiles-multispecific-antibodies-harness-nk-cell-engagers">Biomissile’s multispecific antibodies harness NK cell engagers</a></h1><div class="deals-m-a__topics"><a class="deals-m-a__topic-link" href="/articles/topic/239,84">Cancer</a></div><div class="deals-m-a__teaser">Biomissile Pharmaceuticals Co. Ltd. is developing multispecific antibodies that overcome resistance associated with antibody-drug conjugates via its next-generation natural killer (NK) cell engagers. “ADCs are very efficacious, but they do have a drawback with side effects and resistance, because...</div></div></article> </li> <li class="deals-m-a__item"> <article class="deals-m-a__article -has-image deals-m-a--article"><figure class="deals-m-a__image"><a class="deals-m-a__thumbnail-link" data-eventname="deals-m-a" data-eventcategory="click" data-eventaction="deals-m-a-image" data-eventlabel="https://www.bioworld.com/articles/716962-akribion-harnessing-g-dase-e-nuclease-with-initial-focus-in-cancer" href="https://www.bioworld.com/articles/716962-akribion-harnessing-g-dase-e-nuclease-with-initial-focus-in-cancer"><img class="deals-m-a__image-thumb" alt="RNA" title="RNA" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RNA-illustration.png?height=355&t=1591307138&width=640" /></a></figure><div class="deals-m-a__details deals-m-a__details-1"><h1 class="deals-m-a__headline"><a class="deals-m-a__article-title-link" href="https://www.bioworld.com/articles/716962-akribion-harnessing-g-dase-e-nuclease-with-initial-focus-in-cancer">Akribion harnessing G-dase E nuclease, with initial focus in cancer</a></h1><div class="deals-m-a__topics"><a class="deals-m-a__topic-link" href="/articles/topic/239,84">Cancer</a></div><div class="deals-m-a__teaser">Newco Akribion Therapeutics GmbH has raised €8 million (US$8.3 million) in a seed round to develop a new and potent class of RNA-targeted CRISPR nucleases, which, rather than cleaving specific nucleic acids, can destroy every type of nucleic acid in a cell.</div></div></article> </li> <li class="deals-m-a__item"> <article class="deals-m-a__article -has-image deals-m-a--article"><figure class="deals-m-a__image"><a class="deals-m-a__thumbnail-link" data-eventname="deals-m-a" data-eventcategory="click" data-eventaction="deals-m-a-image" data-eventlabel="https://www.bioworld.com/articles/716685-harness-going-after-new-target-fan-1-in-huntingtons-disease" href="https://www.bioworld.com/articles/716685-harness-going-after-new-target-fan-1-in-huntingtons-disease"><img class="deals-m-a__image-thumb" alt="3D illustration of RNA and proteins" title="3D illustration of RNA and proteins" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/3D-illustration-of-RNA-and-proteins.jpg?height=355&t=1738099271&width=640" /></a></figure><div class="deals-m-a__details deals-m-a__details-1"><h1 class="deals-m-a__headline"><a class="deals-m-a__article-title-link" href="https://www.bioworld.com/articles/716685-harness-going-after-new-target-fan-1-in-huntingtons-disease">Harness going after new target, FAN-1, in Huntington’s disease</a></h1><div class="deals-m-a__topics"><a class="deals-m-a__topic-link" href="/articles/topic/256,84">Neurology/psychiatric</a></div><div class="deals-m-a__teaser">Harness Therapeutics Ltd. has raised fresh financing to further develop its technology for upregulating the translation of mRNA into proteins, and in particular to take on a previously undruggable target in Huntington’s disease.</div></div></article> </li> <li class="deals-m-a__item"> <article class="deals-m-a__article -has-image deals-m-a--article"><figure class="deals-m-a__image"><a class="deals-m-a__thumbnail-link" data-eventname="deals-m-a" data-eventcategory="click" data-eventaction="deals-m-a-image" data-eventlabel="https://www.bioworld.com/articles/716597-linkgevity-targets-aging-as-it-joins-startup-accelerator-kq-labs" href="https://www.bioworld.com/articles/716597-linkgevity-targets-aging-as-it-joins-startup-accelerator-kq-labs"><img class="deals-m-a__image-thumb" alt="Linkgevity founders Carina Kern, CEO (left), and Serena Kern-Libera, COO (right), at the Francis Crick Institute in London" title="Linkgevity founders Carina Kern, CEO (left), and Serena Kern-Libera, COO (right), at the Francis Crick Institute in London" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/BW-source/2025/LinkGevity-founders-1-24.jpg?height=355&t=1737749654&width=640" /></a></figure><div class="deals-m-a__details deals-m-a__details-1"><h1 class="deals-m-a__headline"><a class="deals-m-a__article-title-link" href="https://www.bioworld.com/articles/716597-linkgevity-targets-aging-as-it-joins-startup-accelerator-kq-labs">Linkgevity targets aging as it joins startup accelerator KQ Labs</a></h1><div class="deals-m-a__topics"><a class="deals-m-a__topic-link" href="/articles/topic/566,84">Aging</a></div><div class="deals-m-a__teaser">Newco Linkgevity Ltd. has won backing from the KQ Labs accelerator program at the Francis Crick Institute in London, enabling it to take forward the lead program, an anti-necrotic drug for treating acute kidney injury, and to further develop its AI-driven system for identifying aging-related...</div></div></article> </li> <li class="deals-m-a__item"> <article class="deals-m-a__article -has-image deals-m-a--article"><figure class="deals-m-a__image"><a class="deals-m-a__thumbnail-link" data-eventname="deals-m-a" data-eventcategory="click" data-eventaction="deals-m-a-image" data-eventlabel="https://www.bioworld.com/articles/716586-aussie-spinout-could-change-blood-pressure-paradigm-with-low-dose-poly-pill" href="https://www.bioworld.com/articles/716586-aussie-spinout-could-change-blood-pressure-paradigm-with-low-dose-poly-pill"><img class="deals-m-a__image-thumb" alt="Hand holding white pill" title="Hand holding white pill" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Hand-holding-white-pill.jpg?height=355&t=1737662211&width=640" /></a></figure><div class="deals-m-a__details deals-m-a__details-1"><h1 class="deals-m-a__headline"><a class="deals-m-a__article-title-link" href="https://www.bioworld.com/articles/716586-aussie-spinout-could-change-blood-pressure-paradigm-with-low-dose-poly-pill">Aussie spinout could change blood pressure paradigm with low-dose poly pill</a></h1><div class="deals-m-a__topics"><a class="deals-m-a__topic-link" href="/articles/topic/153,84">Clinical</a></div><div class="deals-m-a__teaser">George Medicines, a new spinout from Australia’s George Institute for Global Health, could offer patients better control of their blood pressure as well as fewer side effects thanks to an ultra-low-dose triple combination. A polypill that combines multiple medicines into a single tablet, GMRx2 was...</div></div></article> </li> </ul><a class="deals-m-a__more-link" data-eventname="deals-m-a" data-eventcategory="click" data-eventaction="deals-m-a-more-link" data-eventlabel="/articles/topic/391-newco-news" href="/articles/topic/391-newco-news">More in Newco news</a> </section></div><section class="topics-section-2__wrapper"><div class="topics-section-2__aside"><section class="asia-pacific "> <h1 class="asia-pacific__title"><a class="asia-pacific__title-link" data-eventname="asia-pacific" data-eventcategory="click" data-eventaction="asia-pacific-title" data-eventlabel="/articles/topic/402-regulatory" href="/articles/topic/402-regulatory">Regulatory</a></h1><ul class="asia-pacific__items"> <li class="asia-pacific__item"> <article class="asia-pacific__article -has-image asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717426-pharmaceuticals-named-as-tariff-target-starting-at-25">Pharmaceuticals named as tariff target, starting at 25%</a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article -has-image asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717424-china-prioritizes-mental-health-pediatric-care-in-2025">China prioritizes mental health, pediatric care in 2025</a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article -has-image asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717355-thousands-of-us-hhs-staff-terminated-in-name-of-efficiency">Thousands of US HHS staff terminated in name of efficiency</a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717354-new-chikungunya-vaccine-from-bavarian-nordic-wins-fda-nod">New chikungunya vaccine from Bavarian Nordic wins FDA nod</a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717353-gsks-meningitis-vaccine-second-pentavalent-approved-by-the-fda">GSK’s meningitis vaccine second pentavalent approved by the FDA</a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article -has-image asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717592-decipheras-romvimza-wins-fda-nod-for-tenosynovial-giant-cell-tumors">Deciphera’s Romvimza wins FDA nod for tenosynovial giant cell tumors </a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article -has-image asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717590-fda-approves-vaccines-for-chikungunya-meningococcal-disease">FDA approves vaccines for chikungunya, meningococcal disease </a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717339-guillain-barre-case-puts-moderna-norovirus-vax-trial-on-hold">Guillain-Barré case puts Moderna norovirus vax trial on hold</a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article -has-image asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717435-nih-funding-plans-threaten-to-derail-synergistic-partnership">NIH funding plans threaten to derail ‘synergistic partnership’</a></h1></article> </li> <li class="asia-pacific__item"> <article class="asia-pacific__article asia-pacific--article"><h1 class="asia-pacific__headline"><a class="asia-pacific__article-title-link" href="https://www.bioworld.com/articles/717258-moleculins-miracle-phase-iii-in-aml-gets-reduced-timeline-stock-burst">Moleculin’s Miracle phase III in AML gets reduced timeline, stock burst</a></h1></article> </li> </ul> </section></div><div class="topics-section-2__row"><div class="topics-section-2__col -one"><section class="bioworld-biome "> <h1 class="bioworld-biome__title"><a class="bioworld-biome__title-link" data-eventname="bioworld-biome" data-eventcategory="click" data-eventaction="bioworld-biome-title" data-eventlabel="/articles/topic/401-u-s" href="/articles/topic/401-u-s">U.S.</a></h1><div class="bioworld-biome__items-wrapper"><ul class="bioworld-biome__items bioworld-biome__items-1"> <li class="bioworld-biome__item"> <article class="bioworld-biome__article bioworld-biome--article"><div class="bioworld-biome__details bioworld-biome__details-1"><h1 class="bioworld-biome__headline"><a class="bioworld-biome__article-title-link" href="https://www.bioworld.com/articles/717657-solid-rocks-dmd-space-with-phase-i-ii-gene-therapy-data">Solid rocks DMD space with phase I/II gene therapy data</a></h1><div class="bioworld-biome__topics"><a class="bioworld-biome__topic-link" href="/articles/topic/153,84">Clinical</a></div><div class="bioworld-biome__teaser">Solid Biosciences Inc. is preparing for a sit-down with the U.S. FDA this year to discuss the firm’s results with the next-generation gene therapy SGT-003 for Duchenne muscular dystrophy (DMD).</div></div></article> </li> </ul><ul class="bioworld-biome__items bioworld-biome__items-2"> <li class="bioworld-biome__item"> <article class="bioworld-biome__article bioworld-biome--article"><h1 class="bioworld-biome__headline"><a class="bioworld-biome__article-title-link" href="https://www.bioworld.com/articles/717356-aaas-2025-car-t-approach-shows-early-promise-in-ms-trial">AAAS 2025: CAR T approach shows early promise in MS trial</a></h1><div class="bioworld-biome__topics"><a class="bioworld-biome__topic-link" href="/articles/topic/153,84">Clinical</a></div></article> </li> <li class="bioworld-biome__item"> <article class="bioworld-biome__article bioworld-biome--article"><h1 class="bioworld-biome__headline"><a class="bioworld-biome__article-title-link" href="https://www.bioworld.com/articles/717341-nectin-4-the-win-corbus-fronts-western-phase-i-with-adc">Nectin-4 the win? Corbus fronts Western phase I with ADC</a></h1><div class="bioworld-biome__topics"><a class="bioworld-biome__topic-link" href="/articles/topic/153,84">Clinical</a></div></article> </li> <li class="bioworld-biome__item"> <article class="bioworld-biome__article bioworld-biome--article"><h1 class="bioworld-biome__headline"><a class="bioworld-biome__article-title-link" href="https://www.bioworld.com/articles/717262-uncharted-territory-for-pliant-after-ipf-trial-pause">Uncharted territory’ for Pliant after IPF trial pause</a></h1><div class="bioworld-biome__topics"><a class="bioworld-biome__topic-link" href="/articles/topic/153,84">Clinical</a></div></article> </li> <li class="bioworld-biome__item"> <article class="bioworld-biome__article -has-image bioworld-biome--article"><h1 class="bioworld-biome__headline"><a class="bioworld-biome__article-title-link" href="https://www.bioworld.com/articles/717257-uncertainty-builds-amid-kennedy-confirmation-trumps-orders">Uncertainty builds amid Kennedy confirmation, Trump’s orders</a></h1><div class="bioworld-biome__topics"><a class="bioworld-biome__topic-link" href="/articles/topic/109,84">Analysis and data insight</a></div></article> </li> </ul></div><a class="bioworld-biome__more-link" data-eventname="bioworld-biome" data-eventcategory="click" data-eventaction="bioworld-biome-more-link" data-eventlabel="/articles/topic/401-u-s" href="/articles/topic/401-u-s">More in U.S.</a> </section></div><div class="adplugg-tag" data-adplugg-zone="bioworld_promo_2"></div></div><div class="topics-section-2__row"><div class="topics-section-2__col -three"><section class="clinical "> <h1 class="clinical__title"><a class="clinical__title-link" data-eventname="clinical" data-eventcategory="click" data-eventaction="clinical-title" data-eventlabel="/articles/topic/396-europe" href="/articles/topic/396-europe">Europe</a></h1><div class="clinical__items-wrapper"><ul class="clinical__items clinical__items-1"> <li class="clinical__item"> <article class="clinical__article -has-image clinical--article"><figure class="clinical__image"><a class="clinical__thumbnail-link" data-eventname="clinical" data-eventcategory="click" data-eventaction="clinical-image" data-eventlabel="https://www.bioworld.com/articles/717072-speculations-rise-on-us-tariff-impact-on-global-pharma-industry" href="https://www.bioworld.com/articles/717072-speculations-rise-on-us-tariff-impact-on-global-pharma-industry"><img class="clinical__image-thumb" alt="Shipping container with flag of China" title="Shipping container with flag of China" width="640" height="355" loading="lazy" src="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Asia/China-export-trade.png?height=355&t=1591831715&width=640" /></a></figure><div class="clinical__details clinical__details-1"><h1 class="clinical__headline"><a class="clinical__article-title-link" href="https://www.bioworld.com/articles/717072-speculations-rise-on-us-tariff-impact-on-global-pharma-industry">Speculations rise on US tariff impact on global pharma industry</a></h1><div class="clinical__topics"><a class="clinical__topic-link" href="/articles/topic/109,84">Analysis and data insight</a></div><div class="clinical__teaser">For the pharmaceutical industry caught in the crosshairs of a potential trade war, the consequences of U.S. tariffs on China or Europe remain largely speculative, although both would be detrimental, according to a Korea Biotechnology Industry Organization (KoreaBIO) issue briefing Feb. 7.</div></div></article> </li> </ul><ul class="clinical__items clinical__items-2"> <li class="clinical__item"> <article class="clinical__article clinical--article"><h1 class="clinical__headline"><a class="clinical__article-title-link" href="https://www.bioworld.com/articles/717001-henlius-lands-european-approval-of-pd-1-lung-cancer-drug">Henlius lands European approval of PD-1 lung cancer drug</a></h1><div class="clinical__topics"><a class="clinical__topic-link" href="/articles/topic/402,84">Regulatory</a></div><div class="clinical__teaser">The European Commission on Feb. 5 cleared Shanghai Henlius Biotech Inc.’s serplulimab (HLX-02) under the brand name of Hetronifly as a first-line combination therapy with carboplatin and etoposide to treat extensive-stage small-cell lung cancer.</div></article> </li> <li class="clinical__item"> <article class="clinical__article clinical--article"><h1 class="clinical__headline"><a class="clinical__article-title-link" href="https://www.bioworld.com/articles/716998-accelerated-approval-mrna-therapies-in-recent-uk-drug-regulations">Accelerated approval, mRNA therapies in recent UK drug regulations</a></h1><div class="clinical__topics"><a class="clinical__topic-link" href="/articles/topic/402,84">Regulatory</a></div><div class="clinical__teaser">The U.K. is continuing to shape up regulation, adding reform of its accelerated drug approval process and its draft guidance on personalized mRNA cancer vaccines to new clinical trial regulations that will come into force early in 2026. The Innovative Licensing and Access Pathway has been...</div></article> </li> </ul><ul class="clinical__items clinical__items-3"> <li class="clinical__item"> <article class="clinical__article -has-image clinical--article"><h1 class="clinical__headline"><a class="clinical__article-title-link" href="https://www.bioworld.com/articles/716979-europe-leads-us-in-cancer-startups-but-lacks-patents-finance">Europe leads US in cancer startups, but lacks patents, finance</a></h1><div class="clinical__topics"><a class="clinical__topic-link" href="/articles/topic/239,84">Cancer</a></div></article> </li> <li class="clinical__item"> <article class="clinical__article -has-image clinical--article"><h1 class="clinical__headline"><a class="clinical__article-title-link" href="https://www.bioworld.com/articles/716868-leqembi-review-stalls-again-at-european-regulator">Leqembi review stalls again at European regulator</a></h1><div class="clinical__topics"><a class="clinical__topic-link" href="/articles/topic/402,84">Regulatory</a></div></article> </li> <li class="clinical__item"> <article class="clinical__article clinical--article"><h1 class="clinical__headline"><a class="clinical__article-title-link" href="https://www.bioworld.com/articles/716799-2025-rebate-hike-in-uk-pricing-deal-putting-sector-at-risk-says-abpi">2025 rebate hike in UK pricing deal putting sector at risk, says ABPI</a></h1><div class="clinical__topics"><a class="clinical__topic-link" href="/articles/topic/402,84">Regulatory</a></div></article> </li> <li class="clinical__item"> <article class="clinical__article clinical--article"><h1 class="clinical__headline"><a class="clinical__article-title-link" href="https://www.bioworld.com/articles/716885-vc-financings-lead-rising-uk-investment-in-2024-analysis-shows">VC financings lead rising UK investment in 2024, analysis shows</a></h1><div class="clinical__topics"><a class="clinical__topic-link" href="/articles/topic/292,84">Financings</a></div></article> </li> </ul></div><a class="clinical__more-link" data-eventname="clinical" data-eventcategory="click" data-eventaction="clinical-more-link" data-eventlabel="/articles/topic/396-europe" href="/articles/topic/396-europe">More in Europe</a> </section></div></div></section><section class="topics-section-3__wrapper"><div class="topics-section-3__col"><section class="regulatory "> <h1 class="regulatory__title"><a class="regulatory__title-link" data-eventname="regulatory" data-eventcategory="click" data-eventaction="regulatory-title" data-eventlabel="/articles/topic/153-clinical" href="/articles/topic/153-clinical">Clinical</a></h1><ul class="regulatory__items"> <li class="regulatory__item"> <article class="regulatory__article -has-image regulatory--article"><h1 class="regulatory__headline"><a class="regulatory__article-title-link" href="https://www.bioworld.com/articles/717422-supernus-phase-iib-results-drag-down-the-stock">Supernus phase IIb results drag down the stock</a></h1><div class="regulatory__topics"><a class="regulatory__topic-link" href="/articles/topic/256,84">Neurology/psychiatric</a></div><div class="regulatory__teaser">The phase IIb study results of Supernus Pharmaceuticals Inc.’s SPN-820 in treatment-resistant depression had pulled the company’s stock (NASDAQ:SUPN) down 15.6% on Feb. 19. The randomized, double-blind, placebo-controlled study of adults failed to...</div></article> </li> <li class="regulatory__item"> <article class="regulatory__article -has-image regulatory--article"><h1 class="regulatory__headline"><a class="regulatory__article-title-link" href="https://www.bioworld.com/articles/717352-septerna-pulls-lead-hypoparathyroidism-drug-on-bilirubin-levels">Septerna pulls lead hypoparathyroidism drug on bilirubin levels</a></h1><div class="regulatory__topics"><a class="regulatory__topic-link" href="/articles/topic/246,84">Endocrine/metabolic</a></div><div class="regulatory__teaser">Septerna Inc.’s stock plunged as much as 68% throughout the day Feb. 18 on news that the company was stopping a phase I trial of SEP-786 in healthy volunteers following two severe events of elevated unconjugated bilirubin in the highest dose...</div></article> </li> <li class="regulatory__item"> <article class="regulatory__article -has-image regulatory--article"><h1 class="regulatory__headline"><a class="regulatory__article-title-link" href="https://www.bioworld.com/articles/717261-bio-ceo-2025-the-quest-for-next-gen-obesity-meds">BIO CEO 2025: The quest for next-gen obesity meds</a></h1><div class="regulatory__topics"><a class="regulatory__topic-link" href="/articles/topic/154,84">Conferences</a></div><div class="regulatory__teaser">While first-generation glucagon-like peptide-1 receptor agonists have clearly taken the obesity market by storm, generating billions of dollars for Novo Nordisk A/S and Eli Lilly and Co., several other companies are developing follow-on products...</div></article> </li> <li class="regulatory__item"> <article class="regulatory__article regulatory--article"><h1 class="regulatory__headline"><a class="regulatory__article-title-link" href="https://www.bioworld.com/articles/717108-re-tool-kit-third-harmonic-sounds-out-options-in-urticaria-bid">(Re-)Tool KIT: Third Harmonic sounds out options in urticaria bid</a></h1><div class="regulatory__topics"><a class="regulatory__topic-link" href="/articles/topic/242,84">Dermatologic</a></div><div class="regulatory__teaser">The closely watched chronic spontaneous urticaria (CSU, or hives) space chalked more early stage KIT inhibitor data as Third Harmonic Bio Inc. rolled out results from the phase I single and multiple ascending-dose trial with THB-335 in healthy...</div></article> </li> <li class="regulatory__item"> <article class="regulatory__article -has-image regulatory--article"><h1 class="regulatory__headline"><a class="regulatory__article-title-link" href="https://www.bioworld.com/articles/717094-4ds-new-data-in-wet-amd-bolster-its-phase-iii-study-vision">4D’s new data in wet AMD bolster its phase III study vision</a></h1><div class="regulatory__topics"><a class="regulatory__topic-link" href="/articles/topic/259,84">Ocular</a></div><div class="regulatory__teaser">4D Molecular Therapeutics Inc.’s gene therapy, 4D-150, in wet age-related macular degeneration (wet AMD) produced positive phase IIb data as the company preps two phase III studies set to begin this year.</div></article> </li> <li class="regulatory__item"> <article class="regulatory__article regulatory--article"><h1 class="regulatory__headline"><a class="regulatory__article-title-link" href="https://www.bioworld.com/articles/717093-pliant-shares-bend-under-ipf-bexotegrast-phase-iib-pause">Pliant shares bend under IPF bexotegrast phase IIb pause</a></h1><div class="regulatory__topics"><a class="regulatory__topic-link" href="/articles/topic/263,84">Respiratory</a></div><div class="regulatory__teaser">A mysterious turn in the phase IIb story with idiopathic pulmonary fibrosis (IPF) candidate bexotegrast sent shares of Pliant Therapeutics Inc. (NASDAQ:PLRX) down 60.6%, or $4.72, to close Feb. 10 at $3.07. </div></article> </li> </ul><a class="regulatory__more-link" data-eventname="regulatory" data-eventcategory="click" data-eventaction="regulatory-more-link" data-eventlabel="/articles/topic/153-clinical" href="/articles/topic/153-clinical">More in Clinical</a> </section></div><div class="topics-section-3__col"><h2><a class="topics-section__title-link" href="https://www.bioworld.com/media/podcasts/532-bioworld-insider-podcast"><strong>BioWorld Insider Podcast</strong></a></h2> <p> <strong>One-on-one with medical innovators</strong> </p> <table style="width: 100%;"><tbody><tr><td style="width: 100.0000%;"> <p class="regulatory__teaser"> <img src="/ext/resources/images/podcast-section-image.png" style="display: inline-block; vertical-align: bottom; margin: 2px 15px 5px 0px; text-align: left; float: left; max-width: calc(100% - 5px); width: 221px;" alt="podcast microphone, sound waves on purple background" data-uuid="YTAtMTA2MzQz" align="left">Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation. </p> </td></tr> <tr><td style="width: 100.0000%;"> <p class="regulatory__teaser"> <br><strong>Recent episodes:</strong> </p> <ul class="regulatory__teaser"> <li><a href="https://www.bioworld.com/media/podcasts/532-bioworld-insider-podcast/play/53-healing-the-health-divide-for-women" rel=" " target="_self">Healing the health divide for women</a></li> <li><a href="https://www.bioworld.com/media/podcasts/532-bioworld-insider-podcast/play/52-modifi-gets-creative-on-the-rocky-road-to-a-multibillion-dollar-buyout" rel=" " target="_self">Modifi gets creative on the rocky road to a multibillion-dollar buyout</a></li> <li><a href="https://www.bioworld.com/media/podcasts/532-bioworld-insider-podcast/play/51-a-quantum-leap-into-the-future-of-drug-development" rel=" noopener noreferrer">A quantum leap into the future of drug development<br></a></li> <li><a href="https://www.bioworld.com/media/podcasts/532-bioworld-insider-podcast/play/50-gene-and-cell-therapies-will-propel-innovation-says-astellas-cco" rel=" noopener noreferrer" target="_self">Gene and cell therapies will propel innovation, says Astellas CCO<br></a></li> <li><a href="https://www.bioworld.com/media/podcasts/532-bioworld-insider-podcast/play/49-capricor-s-ceo-pursues-a-bla-and-talks-rare-disease" rel=" noopener noreferrer">Capricor’s CEO pursues a BLA and talks rare disease<br></a></li> <li><a href="/media/podcasts/532-bioworld-insider-podcast/play/48-the-first-half-of-2024-was-strong-as-m-as-and-financings-dominate" rel=" ">The first half of 2024 was strong as M&As and financings dominate<br></a></li> <li><a href="/media/podcasts/532-bioworld-insider-podcast/play/47-the-cost-of-delays-in-development-and-sales-it-s-probably-not-what-you-think" rel=" ">The cost of delays in development and sales: It’s probably not what you think</a></li> <li><a href="/media/podcasts/532-bioworld-insider-podcast/play/46-asco-preview-adcs-and-radiotherapies-at-the-forefront-of-this-year-s-conference" rel=" " target="_self">ASCO preview: ADCs and radiotherapies at the forefront of this year’s conference<br></a></li> <li><a href="/media/podcasts/532-bioworld-insider-podcast/play/45-fibrobiologics-walks-the-unconventional-financing-path" rel=" " target="_self">Fibrobiologics walks the unconventional financing path<br></a></li> <li><a href="/media/podcasts/532-bioworld-insider-podcast/play/44-back-to-fundamentals-the-latest-numbers-point-to-better-times" rel=" " target="_self">Back to fundamentals: The latest numbers point to better times<br></a></li> </ul> <p class="regulatory__teaser"> <a href="https://www.bioworld.com/media/podcasts/532?audio_file_id=0&id_raw=532&page=1"><u>View all</u></a> </p> </td></tr></tbody></table></div></section><section class="topics-cta__wrapper"><div class="topics-cta"><h1 class="topics-cta__headline">BioWorld</h1><div class="topics-cta__teaser">The news source of record covering the development of innovative human therapies for 25+ years</div><a class="topics-cta__link" href="/order">Subscribe</a></div><div class="topics-cta"><h1 class="topics-cta__headline">BioWorld MedTech</h1><div class="topics-cta__teaser">Actionable and timely intelligence on advances in medical devices and technologies for 20+ years</div><a class="topics-cta__link" href="/order">Subscribe</a></div><div class="topics-cta"><h1 class="topics-cta__headline">BioWorld Asia</h1><div class="topics-cta__teaser">A weekly monitor of biopharmaceutical news from the industry’s fastest-growing region</div><a class="topics-cta__link" href="/order">Subscribe</a></div><div class="topics-cta"><h1 class="topics-cta__headline">BioWorld Science</h1><div class="topics-cta__teaser">Essential discovery and preclinical research news to support crucial drug R&D decisions at the earliest stages</div><a class="topics-cta__link" href="/order">Subscribe</a></div><div class="topics-cta"><h1 class="topics-cta__headline">BioWorld Premium</h1><div class="topics-cta__teaser">Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription</div><a class="topics-cta__link" href="/order">Subscribe</a></div></section></div><footer class="main-footer"><div class="main-footer__top"><nav id="footer-1" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="BioWorld|/topics/84-bioworld" href="/topics/84-bioworld">BioWorld</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Today's news|/topics/84-bioworld" href="/topics/84-bioworld">Today's news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Analysis and data insight|/articles/topic/84,109-analysis-and-data-insight-bioworld" href="/articles/topic/84,109-analysis-and-data-insight-bioworld">Analysis and data insight</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Clinical|/articles/topic/84,153-clinical-bioworld" href="/articles/topic/84,153-clinical-bioworld">Clinical</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Data Snapshots|/snapshots" href="/snapshots">Data Snapshots</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Deals and M&A|/articles/topic/84,214-deals-bioworld" href="/articles/topic/84,214-deals-bioworld">Deals and M&A</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Financings|/articles/topic/84,292-financings-bioworld" href="/articles/topic/84,292-financings-bioworld">Financings</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Newco news|/articles/topic/84,391-newco-news-bioworld" href="/articles/topic/84,391-newco-news-bioworld">Newco news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Opinion|/blogs/1-bioworld-perspectives" href="/blogs/1-bioworld-perspectives">Opinion</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Regulatory|/articles/topic/84,402-regulatory-bioworld" href="/articles/topic/84,402-regulatory-bioworld">Regulatory</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-1" data-eventcategory="click" data-eventaction="footer-1-link" data-eventlabel="Science|/articles/topic/84,110-science-bioworld" href="/articles/topic/84,110-science-bioworld">Science</a></li></ul></li></ul></div></nav><nav id="footer-2" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="BioWorld MedTech|/topics/85-bioworld-medtech" href="/topics/85-bioworld-medtech">BioWorld MedTech</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Today's news|/topics/85-bioworld-medtech" href="/topics/85-bioworld-medtech">Today's news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Clinical|/articles/topic/85,153-clinical-bioworld-medtech" href="/articles/topic/85,153-clinical-bioworld-medtech">Clinical</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Data Snapshots|/medtech_snapshots" href="/medtech_snapshots">Data Snapshots</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Deals and M&A|/articles/topic/85,214-deals-bioworld-medtech" href="/articles/topic/85,214-deals-bioworld-medtech">Deals and M&A</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Financings|/articles/topic/85,292-financings-bioworld-medtech" href="/articles/topic/85,292-financings-bioworld-medtech">Financings</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Newco news|/articles/topic/85,391-newco-news-bioworld-medtech" href="/articles/topic/85,391-newco-news-bioworld-medtech">Newco news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Opinion|/blogs/2-bioworld-medtech-perspectives" href="/blogs/2-bioworld-medtech-perspectives">Opinion</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Regulatory|/articles/topic/85,402-regulatory-bioworld-medtech" href="/articles/topic/85,402-regulatory-bioworld-medtech">Regulatory</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-2" data-eventcategory="click" data-eventaction="footer-2-link" data-eventlabel="Science|/articles/topic/85,110-science-bioworld-medtech" href="/articles/topic/85,110-science-bioworld-medtech">Science</a></li></ul></li></ul></div></nav><nav id="footer-3" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="BioWorld Asia|/topics/86-bioworld-asia" href="/topics/86-bioworld-asia">BioWorld Asia</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Today's news|/topics/86-bioworld-asia" href="/topics/86-bioworld-asia">Today's news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Analysis and data insight|/articles/topic/86,109-analysis-and-data-insight-bioworld-asia" href="/articles/topic/86,109-analysis-and-data-insight-bioworld-asia">Analysis and data insight</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Australia|/articles/topic/86,394-australia-bioworld-asia" href="/articles/topic/86,394-australia-bioworld-asia">Australia</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="China|/articles/topic/86,395-china-bioworld-asia" href="/articles/topic/86,395-china-bioworld-asia">China</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Clinical|/articles/topic/86,153-clinical-bioworld-asia" href="/articles/topic/86,153-clinical-bioworld-asia">Clinical</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Deals and M&A|/articles/topic/86,214-deals-bioworld-asia" href="/articles/topic/86,214-deals-bioworld-asia">Deals and M&A</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Financings|/articles/topic/86,292-financings-bioworld-asia" href="/articles/topic/86,292-financings-bioworld-asia">Financings</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Newco news|/articles/topic/86,391-newco-news-bioworld-asia" href="/articles/topic/86,391-newco-news-bioworld-asia">Newco news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Regulatory|/articles/topic/86,402-regulatory-bioworld-asia" href="/articles/topic/86,402-regulatory-bioworld-asia">Regulatory</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-3" data-eventcategory="click" data-eventaction="footer-3-link" data-eventlabel="Science|/articles/topic/86,110-science-bioworld-asia" href="/articles/topic/86,110-science-bioworld-asia">Science</a></li></ul></li></ul></div></nav><nav id="footer-5" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="BioWorld Science|/topics/520-bioworld-science" href="/topics/520-bioworld-science">BioWorld Science</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Today's news|/topics/520-bioworld-science" href="/topics/520-bioworld-science">Today's news</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Biomarkers|/articles/topic/520,543-biomarkers-bioworld-science" href="/articles/topic/520,543-biomarkers-bioworld-science">Biomarkers</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Cancer|/articles/topic/520,239-cancer-bioworld-science" href="/articles/topic/520,239-cancer-bioworld-science">Cancer</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Conferences|/articles/topic/520,154-conferences-bioworld-science" href="/articles/topic/520,154-conferences-bioworld-science">Conferences</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Endocrine/Metabolic|/articles/topic/520,246-endocrine-metabolic-bioworld-science" href="/articles/topic/520,246-endocrine-metabolic-bioworld-science">Endocrine/Metabolic</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Immune|/articles/topic/520,250-immune-bioworld-science" href="/articles/topic/520,250-immune-bioworld-science">Immune</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Infection|/articles/topic/520,251-infection-bioworld-science" href="/articles/topic/520,251-infection-bioworld-science">Infection</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Neurology/Psychiatric|/articles/topic/520,256-neurology-psychiatric-bioworld-science" href="/articles/topic/520,256-neurology-psychiatric-bioworld-science">Neurology/Psychiatric</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-5" data-eventcategory="click" data-eventaction="footer-5-link" data-eventlabel="Patents|/articles/topic/520,472-patents-bioworld-science" href="/articles/topic/520,472-patents-bioworld-science">Patents</a></li></ul></li></ul></div></nav><nav id="footer-4" class="main-footer__nav"><div class="navigation"><ul class="main-footer__nav-level1__items"><li class="main-footer__nav-level1__item"><a class="main-footer__nav__link -has-children" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="More|javascript:void(0);" href="javascript:void(0);">More</a><ul class="main-footer__nav-level2__items"><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="About|/about" href="/about">About</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Advertise with BioWorld|/advertising" href="/advertising">Advertise with BioWorld</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Archives|/newsletters" href="/newsletters">Archives</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Article reprints and permissions|/reprints" href="/reprints">Article reprints and permissions</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Contact us|https://clarivate.com/cortellis/contact-us/" target="_blank" href="https://clarivate.com/cortellis/contact-us/">Contact us</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Cookie policy|https://clarivate.com/legal/cookie-policy/" target="_blank" href="https://clarivate.com/legal/cookie-policy/">Cookie policy</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Copyright notice|https://clarivate.com/legal/copyright-notice/" target="_blank" href="https://clarivate.com/legal/copyright-notice/">Copyright notice</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Data methodology|/content/methodology-chart" href="/content/methodology-chart">Data methodology</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Infographics: Dynamic digital data analysis|/infographics-index" href="/infographics-index">Infographics: Dynamic digital data analysis</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Podcasts|/media/podcasts/532-bioworld-insider-podcast" href="/media/podcasts/532-bioworld-insider-podcast">Podcasts</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Privacy policy|https://clarivate.com/legal/privacy-policy/" target="_blank" href="https://clarivate.com/legal/privacy-policy/">Privacy policy</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Share your news with BioWorld|/share_your_news" href="/share_your_news">Share your news with BioWorld</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Staff|/staff" href="/staff">Staff</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Terms of use|https://clarivate.com/legal/terms-of-use/" target="_blank" href="https://clarivate.com/legal/terms-of-use/">Terms of use</a></li><li class="main-footer__nav-level2__item"><a class="main-footer__nav__link" data-eventname="footer-4" data-eventcategory="click" data-eventaction="footer-4-link" data-eventlabel="Topic alerts|/rss" href="/rss">Topic alerts</a></li></ul></li></ul></div></nav></div><div class="main-footer__bottom"><a class="social-media-links" title="Follow us" href="/social-media"><div class="social-media-links__callout">Follow Us</div><div class="social-media-links__twitter"></div> <div class="social-media-links__linkedin"></div></a></div><p class="main-footer__copyright">Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: <a href="http://www.epublishing.com" target="_blank">ePublishing</a><br /><button class="ot-sdk-show-settings" id="ot-sdk-btn" style="margin-top: 1rem">Cookie Settings</button></p></footer></div> <script async="async"> //<![CDATA[ require(['bundle/main.bundle']); //]]> </script> </body></html>